|Agenus Inc -- Germany Stock|| |
EUR 4.46 0.23 4.90%
Chief Business Officer
Mr. Ozer Baysal is Chief Commercial Officer, Head of HR of Agenus Inc. Mr. Baysal was Chief Business Officer since January 2013 until July 1, 2017. Prior to joining Agenus Mr. Baysal spent more than 30 years with Pfizer in a broad number of functional and geographic areas, most recently serving as President of Europe, Emerging Markets Region. While at Pfizer, he held key leadership positions in Marketing, Sales, and Manufacturing, and was actively involved with numerous licensing and MA activities
Age: 60 Executive Since 2017
Baysal holds a bachelor degree from Bosphorus University in Industrial Engineering and has completed the Programs for Leadership and Management Development at Harvard Business School.
The company has return on total asset (ROA)
of (39.63) %
which means that it has lost $39.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (421.01) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 143.94 M in total debt. Agenus Inc has Current Ratio of 1.52 which is within standard range for the sector.
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system for patients suffering with cancer. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus is traded on Frankfurt Stock Exchange in Germany.Agenus Inc (AJ81) is traded on Frankfurt Stock Exchange in Germany. It is located in 3 Forbes Road and employs 255 people.